MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are prevalent in various cancers and are associated with therapeutic resistance.
• Understanding the molecular mechanisms underlying NF1-associated cancers is crucial for developing effective treatments.

Purpose of the Study:

• To identify and characterize NF1-regulated genes involved in malignant peripheral nerve sheath tumor (MPNST) development.
• To investigate the role of the transcription factor MAF in NF1-deficient MPNSTs and its impact on tumor growth and signaling pathways.

Main Methods:

• Transcriptome analysis to identify NF1-regulated genes.
• In vitro studies using MPNST cell lines to assess MAF expression and function.
• In vivo tumor xenograft models to evaluate the effect of MAF overexpression on tumor growth.
• Western blot analysis to examine protein expression and pathway activation (e.g., mTOR, MAPK).

Main Results:

• MAF was identified as an NF1-regulated transcription factor, downregulated in human MPNSTs.
• Acute MAF re-expression in MPNST cells promoted glial differentiation, reduced self-renewal, and inhibited tumor cell phenotypes in vitro.
• Paradoxically, chronic MAF overexpression enhanced MPNST tumor growth in vivo, associated with elevated pS6 and mTOR pathway activation.
• MAF regulates the mTOR pathway via DEPTOR, and RAD001 (an mTOR inhibitor) blocked MAF-mediated tumor growth.

Conclusions:

• MAF plays a complex, context-dependent role in NF1-associated MPNSTs.
• While acute MAF expression can be tumor-suppressive, chronic overexpression promotes tumor growth through mTOR pathway activation.
• MAPK pathway inhibition may have limited efficacy in NF1-deficient tumors due to MAF-mediated mTOR reactivation, suggesting therapeutic strategies targeting the mTOR pathway are warranted.